Impact of assessment and treatment of neuropathic pain in patients with chronic diabetic neuropathy assisted in a diabetes reference service by Carolina Ritzmann et al.
MEETING ABSTRACT Open Access
Impact of assessment and treatment of
neuropathic pain in patients with chronic diabetic
neuropathy assisted in a diabetes reference service
Carolina Ritzmann, Lucia Henriques Alves da Silva*, Rosane Kupfer
From 20th Brazilian Diabetes Society Congress
Porto Alegre, Brazil. 11-18 November 2015
Background
Diabetic neuropathy is one of the chronic complications
of hyperglycemia, which characterizes Diabetes Mellitus.
As a result of an indolent course, the absence of signs and
symptoms and nonspecific manifestations, it can remain
undiagnosed for a long time. One of the clinical presenta-
tions is the presence of neuropathic symptoms, such as
pain, cramps or paresthesia, which can compromise the
quality of life.
Objective
The objective of this study was to demonstrate that the
pharmacological treatment of neuropathic pain can pro-
mote a significant symptomatic improvement assessed by
validated scores and that the establishment of a support
center in neuropathy constitutes an important measure in
the context of multidisciplinary care of the diabetic
patient.
Materials and methods
53 patients were recruited with a mean age of 58 yrs.,
similar gender distribution (50.9% male and 49.1% female),
mostly with type 2 Diabetes Mellitus (83%), average diag-
nosis time of 18 yrs. and median time for neuropathic
symptoms of 2 yrs.
Results
At the first visit, subjects had pain intensity classified as
moderate by the Analog Pain Scale, intensity of neuropathic
symptoms classified as severe (56.6%) and neuropathic
disability rated as moderate to severe impairment (41.5%).
Following the prescription of specific pharmacological
treatment, 91.6% of patients reported maintenance or
improvement of symptoms and only 2.8% reported worsen-
ing. It was observed significant improvement in Neuro-
pathic Symptoms Score (p=0.0006) and Analogic Pain
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Figure 1 Baseline characteristics of the patients. # values
expressed in relative frequency; Analogic Pain Scale: 0-2: mild; 3-7
moderate; 8-10: severe; Neuropathic Symptoms Score: 1-4: mild; 5-6
moderate; 7-10: severe; Neuropathic Disability Score 3-5: mild; 6-8:
moderate; 9-10: severe; Uncooperative patients: patients in whose
Achilles reflex couldn't be assessed; No information: information not
find at the records.
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Scale (p <0.0001), especially in type 2 diabetic group. There
was no change in Neuropathic Disability Score.
Conclusion
This study demonstrated that the existence of a support
center for assessment and treatment of painful diabetic
neuropathy in a Diabetes reference service allows early
diagnosis and intervention in neuropathic symptoms in
an effective way.
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Figure 2 Comparison between clinical parameters before and
after pharmacologic treatment of pain. *statistically significant P-
value (< 0.05); # values expressed in relative frequency; Analogic
Pain Scale: 0-2: mild; 3-7 moderate; 8-10: severe; Neuropathic
Symptoms Score: 1-4: mild; 5-6 moderate; 7-10: severe; Neuropathic
Disability Score 3-5: mild; 6-8: moderate; 9-10: severe; Uncooperative
patients: patients in whose Achilles reflex couldn't be assessed; No
information: information not find at the records
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